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Parkinsonism is one of the major neurodegenerative disorders worldwide. Substantia nigra pars compacta of the central nervous system exhibits differential vulnerability to various etiological factors of Parkinson\'s disease. Parkinson\'s disease results from several pathological and molecular events that provoke neurodegeneration of dopaminergic neurons.\[[@ref1][@ref2]\] Soluble guanylate cyclase (sGC) enzyme was reported abundantly in striatal medium spiny neurons (MSN). MSNs were largely located in direct and indirect tracts of the basal ganglia\[[@ref3][@ref4][@ref5]\] and involved in normal physiological functions of the basal ganglia such as motor activity control\[[@ref6]\] as demonstrated in [Figure 1](#F1){ref-type="fig"}. The direct pathways include D~1~ receptors which increase excitatory thalamic input to cerebral cortex and increase the motor activity. The indirect tracts include D~2~ receptors which decrease the thalamic input to cerebral cortex and the motor activity. In Parkinson\'s disease, MSN degeneration is due to various pathological and molecular mechanisms. These molecular and pathological changes in Parkinson\'s disease may lead to movement disorders such as hypokinesia, tremors, molecular rigidity, slowing of gait, and reduced agility.\[[@ref7]\] This neuronal dysfunction may be aggravated due to persistent activation of neuronal pathways, leading to Parkinson\'s disease.\[[@ref8]\] Cyclic guanosine monophosphate (cGMP) pathway was considered to be potential pathway in neurotransmission at striatal level.\[[@ref9]\] sGC is an important enzyme protein in cGMP pathway\[[@ref10]\] which when derailed may be a causative factor for Parkinson\'s disease or aggravation of changes in Parkinson\'s disease. As pathogenesis of Parkinson\'s disease is multifactorial, sGC-cGMP pathway was considered to review the role of sGC as a causative factor. The effect of neurotoxins on sGC in Parkinson\'s disease and sGC inhibitors in Parkinson\'s disease was reviewed. The role of sGC in neurodegeneration and Parkinson\'s disease was reviewed by exploring the literature using PubMed and EMBASE. Databases were searched using the following terms: Parkinson\'s disease, neurotoxins, guanylate cyclase, sGC-cGMP pathway, and neurodegeneration.
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sGC (EC 4.6.1.2) is a type of guanylate cyclase enzyme belonging to the family lyases.\[[@ref11]\] Structurally sGC is a heterodimeric protein compound consisting of two subunits α and β \[[Figure 2](#F2){ref-type="fig"}\]. α1, α2, α2i, β1, β2 are the isoforms of sGC.\[[@ref12][@ref13]\] Most common sGC isoform in the brain is α1β1,\[[@ref14][@ref15]\] and α2 was also found in the human fetal brain.\[[@ref16]\] β subunit consists of enzyme activating site with heme residues, but both subunits are required for activating the enzyme.\[[@ref17]\] This enzyme can be affected by neurotransmitters in the brain\[[@ref18]\] increasing cGMP levels\[[@ref19]\] which is responsible for glutamate neurotransmission and chronic effects in synaptic transmission.\[[@ref20]\] Localization of sGC in the specific regions of the brain may be related to some of the abnormalities in a pathological state or to the pathological condition of a particular part of the brain. An *in situ* hybridization study of rat brain revealed that sGC activity in striatum is 2.5--3 times more in comparison to other parts of thebrain\[[@ref21]\] \[[Figure 3](#F3){ref-type="fig"}\]. Immunohistochemical findings of a study had revealed the presence of guanylate cyclase activity abundant in caudate putamen complex but could not state whether it is a soluble type or particulate type of guanylate cyclase.\[[@ref22]\]
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sGC-cGMP pathway is a physiological process for synthesis of cGMP from guanosine triphosphate which leads to the activation of protein kinases to cause various biochemical changes at cellular level.\[[@ref23]\] Stimulation of sGC increases cellular Ca^+2^ levels due to activation of protein kinase-dependent ion channels.\[[@ref24]\] This increased Ca^+2^ causes stimulation of glutamate receptors responsible for glutamate transmission in MSN of direct and indirect dopaminergic tracts.\[[@ref25][@ref26]\] This glutamate in turn also regulates the sGC activation through regulation of neuronal nitric oxide (NO) synthase\[[@ref27]\] or through phosphodiesterases, which metabolizes cGMP.\[[@ref28][@ref29]\] When there is excess stimulation of sGC, it causes glutamate toxicity and apoptosis. These are the normal and abnormal events of the sGC-cGMP pathway \[[Figure 4](#F4){ref-type="fig"}\].
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Pathological consequences of this pathway may be excess glutamate transmission, resulting in abnormal motor behavior in the animals or humans,\[[@ref30][@ref31]\] and this glutamate toxicity may cause generation of reactive oxygen species (ROS) at cellular level, leading to apoptosis of neuronal cells in dopaminergic tracts.\[[@ref32][@ref33]\] Over-expression of this enzyme may be of various reasons which may also include genetic variations or abnormalities. First factor of over-expression of sGC may be excess stimulation causing excess production of cGMP which in turn leads to excess glutamate activity.\[[@ref34]\] This augmented glutamate activity was considered toxic leading to apoptosis of neurons\[[@ref35]\] which may be caspase dependent or independent depending on the site of excess glutamate activity in the brain.\[[@ref36][@ref37]\] The excess glutamate activity causes influx of Ca^+2^ ions into neurons which leads to increase Ca^+2^ ion concentration intracellularly.\[[@ref38]\] This results in mitochondrial dysfunction leading to inhibition of respiratory chain and ROS accumulation. These mitochondrial dysfunction and ROS generation signals may activate caspase-dependent apoptosis.\[[@ref37][@ref39]\] Here, activation of sGC was reviewed and listed various factors which may activate sGC and be a causative factor for Parkinson\'s disease or an aggravation factor for the disease symptoms of Parkinson\'s disease. Apart from NO which has been considered as the principal activator of sGC,\[[@ref40]\] carbon monoxide (CO), lead (Pb^+2^), manganese (Mn^+2^), aluminum (Al^+3^), 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), hydroxydopamine (6-OHDA), and paraquat may also affect the sGC activity.

CO is abundantly available in the environment due to pollution.\[[@ref41]\] This can chronically affect the sGC leading to the changes in striatum.\[[@ref42]\] CO exposure resulting in Parkinson\'s disease was reported by many observational studies all over the world.\[[@ref43][@ref44][@ref45][@ref46]\] CO binds to heme part of sGC at the same binding site of NO\[[@ref47]\] and causes its stimulation by formation of carbonyl-heme complex.\[[@ref48][@ref49]\] Preclinical studies revealed that CO can stimulate sGC but not as strong as NO.\[[@ref48]\] Although CO is a weak stimulator of sGC, it may not have controlling mechanisms such as NO. Stimulation of sGC with NO is regulated by glutamate-dependent neuronal NO synthase. Hence, there may be a considerable effect due to CO on sGC affecting striatal dopaminergic system through glutamate toxicity. A study reported that CO may also be formed from hemeoxygenase in the brain.\[[@ref50]\] There may be aggravation of CO action on sGC either by increased CO levels in corpus striatum or due to compromise in neurotrophic factors and glutathione.

Pb^+2^ exposure although controlled in many ways by regulation of pollution boards and food and drug regulatory bodies, there is still considerable exposure to humans through various sources\[[@ref51][@ref52]\] affecting or causing diseases even at blood lead levels of \< 10μg/dL.\[[@ref53][@ref54]\] Clinical studies have reported increased risk of Parkinson\'s disease upon exposure to lead substances.\[[@ref55]\] Till now, direct effects of Pb on sGC in the brain were not reported, but it may affect indirectly by causing accumulation of arachidonic acid\[[@ref56]\] which is also a stimulator of sGC similar to CO and NO.\[[@ref57]\] Some studies revealed that there is downregulation of sGC activity in the aorta when subjected to lead in an hypertension animal model.\[[@ref58]\] Further studies are required to evaluate the effects of lead on sGC in brain.

Magnesium (Mg^+2^) is an important factor facilitating production of cGMP as a cofactor for the enzyme reaction.\[[@ref59][@ref60]\] Activity of guanylate cyclase is more active with Mn^+2^ than Mg^+2^,\[[@ref61]\] but selectivity of Mn^+2^ on the type of guanylate cyclase has to be studied. Here, it may be concluded that any association or availability of even weak stimulators of sGC with increased Mg^+2^ or Mn^+2^ levels in the brain may lead to excess cGMP formation and glutamate toxicity in brain.

Aluminum exposure is common as it\'s availability is 8% (approximately) in the earth crust. It is being exposed to humans in various forms through air, food, and water. There are clinical studies which had reported the involvement of aluminum in Parkinson\'s disease.\[[@ref62][@ref63][@ref64][@ref65]\] Aluminum in the form of salts such as aluminum citrate and aluminum sulfate was reported to increase cyclic GMP levels variably at different sites of brain;\[[@ref66]\] this may involve the role of sGC. Further, studies are required to evaluate role of sGC stimulated by aluminum leading to Parkinson\'s disease.

MPTP is a neurotoxin, increasing the activity of sGC and raising the levels of cGMP in the brain, particularly in striatal neurons.\[[@ref67]\] This may lead to increased glutamate activity and result in apoptosis of striatal neurons. Another neurotoxin 6-OHDA has also been reported to increase the striatal cGMP levels abnormally,\[[@ref68]\] which may indicate its role in activation of sGC and striatal neurons apoptosis.

Paraquat, as a pesticide neurotoxin causing Parkinson\'s disease both in human\[[@ref69]\] and animals,\[[@ref70]\] is known. Preclinical studies reported that paraquat had caused loss of striatal fibers in a dose-dependent manner.\[[@ref71][@ref72][@ref73][@ref74]\] There are studies which revealed increase in NO activity when subjected to paraquat\[[@ref75]\] and also competitive inhibition of paraquat-induced ROS formation by methylene blue which is an sGC inhibitor.\[[@ref76]\] The direct activity of paraquat with sGC in the brain is not yet known, but it is known to stimulate particulate guanylate cyclase and increase the levels of cGMP in the lungs resulting cystic fibrosis.\[[@ref77]\]
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In the above section, the importance of sGC in etiopathogenesis of Parkinson\'s disease has been demonstrated. Now, it may be stated that use of guanylate cyclase inhibitors may stop the progression of Parkinson\'s disease which may attenuate the apoptosis of striatal neurons. Preclinical studies reported that sGC inhibitor such as 1H-[@ref1]2,[@ref4] oxadiazolo-[@ref4]3-a\] quinoxalin-1-one improved corticostriatal synaptic transmission and the motor behavior in mice models of MPTP and 6-OHDA.\[[@ref68]\] Another study reported the presence of endogenous sGC inhibitor (CCTη) which inhibits the enzyme in a different manner without affecting the binding of NO.\[[@ref78]\] Zn^+2^, Cd^+2^, and Hg^+2^ have shown inhibitory effect on guanylate cyclase.\[[@ref61]\] Further studies can be made in more detail to achieve the long-term safety of these drugs preclinically for their clinical usage.
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sGC being the key enzyme for the synthesis of cGMP and one of the responsible factors for causing apoptosis through glutamate toxicity may be considered as a causative factor or aggravating factor of Parkinson\'s disease. This review listed out the factors that have probability for stimulating sGC which was already listed as neurotoxins causing Parkinson\'s disease. As Parkinson\'s disease is multifactorial and is likely to involve different causes in different patients, there is a necessity to identify an alternative nondopaminergic mechanism. The sGC-cGMP signaling cascade is an emerging candidate for second messenger-based therapies of Parkinson\'s disease. Genetic variability and polymorphism of sGC in the brain can also be studied to improve the treatment strategies of Parkinson\'s disease.
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